US-based XOMA Corporation (XOMA) has received Orphan Drug Designation from the US Food and Drug Administration (FDA) for its IL-1 beta modulating antibody 'gevokizumab' for the treatment of pyoderma gangrenosum (PG). Gevokizumab is a ...
Tags: Orphan Drug, Medicine
Their joint aim is to identify new therapeutic targets in ‘triple negative’ breast cancers Curie-Cancer, the body which leads the Institut Curie's industry partner research activity, and Servier, today announce that they have ...
Tags: triple negative, Curie-Cancer, TTK/MPS1, Institut Curie and Servier
Galapagos, a mid-size biotechnology company, has delivered the first pre-clinical candidate compound in its osteoarthritis alliance with Servier. Servier and Galapagos entered into an alliance in July 2010 to develop new oral medicines ...
Tags: Galapagos Identifies Drug, Galapagos, Servier, osteoarthritis
Vernalis has reached a research milestone as part of the oncology drug discovery alliance with French pharmaceutical company, Servier. Under the drug discovery program, Vernalis will receive a payment of €0.5m from Servier on ...
Tags: drug discovery platforms, oncology drug discovery, undisclosed oncology